MiNK Therapeutics, Inc. — FY 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 21, 2024. This is an annual report, not a standalone fourth-quarter report. MiNK is a clinical-stage biotechnology company developing allogeneic invariant natural killer T-cell (iNKT) therapies. It has no approved products and reported no product or royalty revenue.
Financial performance and position
| Metric | FY 2023 / Dec. 31, 2023 | FY 2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $15.5 million | $23.1 million |
| General and administrative expense | $7.4 million | $7.8 million |
| Operating loss | $22.9 million | $30.9 million |
| Net loss | $22.5 million; $0.65 per share | $28.0 million; $0.83 per share |
| Net cash used in operating activities | $15.8 million | $18.9 million |
| Cash and cash equivalents | $3.4 million | $19.6 million |
| Total current assets / current liabilities | $3.6 million / $11.4 million | $20.4 million / $12.7 million |
MiNK has accumulated losses of $133.4 million. Its current-liability excess over current assets was approximately $7.8 million at year-end. The balance sheet reports $11.2 million due to related parties, principally Agenus; Agenus agreed not to require repayment before March 31, 2025. The filing reports no operating margin or product gross margin because the company has no product revenue.
Changes versus 2022
- Net loss narrowed by about $5.5 million, primarily as R&D expense fell 33% and G&A expense fell 5%.
- The 2022 result included a $2.7 million gain related to partial forgiveness/reduction of a Walloon Region repayable advance; 2023 had no comparable gain. A remaining approximately $2.3 million balance is recorded as a current liability and relates to a repayment judgment.
- Cash declined by $16.3 million during 2023. Operating cash use improved by approximately $3.1 million year over year.
Programs, outlook and key risks
- Lead program: agenT-797, an off-the-shelf native iNKT cell therapy, is in Phase 1 development for refractory solid tumors and viral ARDS. The company reported early antitumor activity, including durable disease stabilization and a gastric cancer partial response; a Phase 2 investigator-sponsored combination study in advanced esophageal, gastric or gastroesophageal-junction cancers was launched, with an intended enrollment of about 38 patients.
- ARDS data: The filing reports survival above 70% among 21 mechanically ventilated patients and 80% among five patients on VV ECMO, compared with reported in-hospital controls. The MD&A separately describes survival as 75% and cites comparator estimates of approximately 10–22%. These are early study findings, not evidence of established comparative efficacy. Management plans to pursue further ARDS development through an externally funded platform trial.
- Pipeline: MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT) remain preclinical. IND-enabling work for MiNK-215 was underway, with a 2024 IND submission anticipated. In December 2023, MiNK entered a discovery and development collaboration with ImmunoScape for next-generation TCR therapies.
- Funding and going concern: Management says year-end cash, post-year-end Agenus funding and planned third-party funding should cover liquidity needs for more than one year after issuance. However, the auditor’s report and filing state that substantial doubt exists about MiNK’s ability to continue as a going concern, because additional funding depends on uncertain sources. In March 2024, MiNK received $5.0 million from Agenus under a convertible note facility; the note bears 2% interest and is payable on demand on or after January 1, 2026, with provisions for a qualified financing event.
- Principal risks: Dependence on Agenus for funding, services and facilities; no approved products or recurring product revenue; early-stage clinical evidence and trial-enrollment uncertainty; manufacturing and regulatory risks; competition; and potential dilution or unfavorable financing terms. Agenus owns approximately 63% of MiNK’s common stock and can substantially influence corporate decisions.
- Nasdaq: MiNK received notices in February 2024 for failure to meet the $35 million minimum market value of listed securities and $1 minimum bid-price requirements. The stated initial compliance deadlines were August 21 and August 26, 2024, respectively; failure to regain compliance could lead to delisting.
Important facts for investors to verify
- Actual cash runway and the terms, availability and timing of any planned third-party financing, given the going-concern warning and the reliance on Agenus.
- Whether clinical updates confirm the reported agenT-797 response, durability, safety and ARDS survival findings in larger, controlled studies.
- Progress and timing of the agenT-797 Phase 2 study and MiNK-215 IND submission, as well as funding to advance both programs.
- Status and treatment of the Walloon Region repayment liability, and the terms and outstanding balance of the Agenus convertible note.
- Nasdaq compliance status, potential dilution from financing and equity awards, and changes in Agenus ownership or related-party arrangements.